Exhibit 99.1

Contact: Merilee Raines, Chief Financial Officer, (207) 856-8155

FOR IMMEDIATE RELEASE

IDEXX Laboratories Announces First Quarter Results

WESTBROOK, Maine, April 29, 2005 — IDEXX Laboratories, Inc. (NASDAQ: IDXX), today reported that revenue for the first quarter of 2005 increased 14% to $152.4 million from $133.4 million for the first quarter of 2004.

          Net income was $17.7 million for the quarter ended March 31, 2005, compared to $17.8 million for the same period in the prior year. Net income, as expected, was flat relative to the first quarter of 2004 primarily as a result of anticipated increases in sales and marketing expense related to the expansion of the Companion Animal Group sales and support personnel in 2004 and integration costs associated with the acquisitions of Vet Med Lab and Dr. Bommeli AG in the fourth quarter 2004.

          Earnings per diluted share for the quarter were $0.51, a 4% increase over earnings per diluted share of $0.49 for the quarter ended March 31, 2004. During the quarter ended March 31, 2005 the Company incurred acquisition integration costs of $0.02 per diluted share associated with the acquisitions of Vet Med Lab and Dr. Bommeli AG. Excluding the effects of these discrete costs in the first quarter of 2005, earnings per diluted share grew 8%.

          Companion Animal Group (CAG) revenue for the first quarter of 2005 increased 14% to $124.9 million from $109.8 million for the first quarter of 2004. This increase resulted primarily from increased sales of laboratory and consulting services, instruments and consumables and, to a lesser degree, pharmaceutical products and rapid assay products. The increase in laboratory and consulting services revenue was due, in part, to the inclusion of sales from laboratories acquired during 2004, which contributed approximately 7% to CAG revenue growth during the quarter. The favorable impact of foreign currency contributed 1% to CAG revenue growth.

          Water segment revenue for the first quarter increased 8% to $12.8 million from $11.9 million for the first quarter of 2004 primarily due to higher worldwide sales volume. The favorable impact of foreign currency contributed 2% to Water revenue growth.

          Food Diagnostics Group (FDG) revenue for the first quarter increased 26% to $14.7 million from $11.7 million for the first quarter of 2004 primarily due to higher production animal diagnostics sales in Europe. Approximately 11% of FDG growth resulted from sales from businesses acquired in 2004. The impact of foreign currency contributed 3% to FDG revenue growth.

IDEXX Announces First Quarter Results
April 29, 2005
Page 2 of 7

          “Our first quarter revenues were in line with our expectations and earnings per share slightly exceeded expectations primarily as a result of higher than anticipated gross margin,” said Jonathan Ayers, Chairman and CEO. “Our results reflect our first full quarter of operations of Vet Med Lab and Dr. Bommeli AG, which we acquired in the fourth quarter of 2004. To date we are very pleased with the performance of these businesses and we are excited about the possibilities for market expansion that these Europe-based companies bring to IDEXX.”

          “Overall we continue to view 2005 as a year in which we integrate our recently acquired businesses and continue to invest in new product and operating initiatives that will position us to achieve our long-term growth objectives.”

Outlook

          The Company offers the following guidance for the second quarter of 2005:

• Revenue is expected to be approximately $160 to $162 million.

• Diluted earnings per share are expected to be approximately $0.56 to $0.58, which includes approximately $0.01 of anticipated acquisition integration costs.

          The Company offers the following guidance for the full year of 2005:

• Revenue is expected to be approximately $630 to $640 million.

• Diluted earnings per share are expected to be approximately $2.25 to $2.28, which includes approximately $0.05 of anticipated acquisition integration costs.

Annual Meeting to be Broadcast Live on Internet

          IDEXX Laboratories, Inc. today announced that it will host a simultaneous Webcast of its Annual Meeting of Stockholders, to be held on Wednesday, May 18, 2005, at 10:00 a.m. (eastern) at the Eastland Park Hotel in Portland, Maine.

          Chairman and CEO Jonathan Ayers will chair the meeting. Investors may listen to the Annual Meeting and view a simultaneous presentation live via a link on the Company’s Web site, idexx.com. An archived edition of the Meeting will be available after 1:00 p.m. (eastern) on that day via the same link.

About IDEXX Laboratories

          IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice-management systems and therapeutics. Our products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs more than 3,000 people and offers products to customers in over 100 countries.

IDEXX Announces First Quarter Results
April 29, 2005
Page 3 of 7

Note Regarding Forward-Looking Statements

This press release contains statements about the Company’s business prospects and estimates of the Company’s financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company’s sales and marketing activities; the Company’s ability to develop, license or obtain rights to new technologies; the Company’s ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company’s products; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the Company’s products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of our products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company’s inventories; the Company’s ability to manufacture complex biologic products; the effects of operations outside the U.S., including  from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2004, in the section captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

IDEXX Announces First Quarter Results
April 29, 2005
Page 4 of 7

IDEXX Laboratories, Inc. and Subsidiaries
Consolidated Statement of Operations
Amounts in thousands except per share data (Unaudited)

		Three Months Ended
		March 31, 2005		March 31, 2004
Revenue:	Revenue	$	152,426	$	133,417
Expenses and
Income:	Cost of revenue		76,346		66,371
	Gross profit		76,080		67,046
	Sales and marketing		25,070		20,983
	General and administrative		15,098		12,242
	Research and development		9,774		8,520
	Income from operations		26,138		25,301
	Interest income, net		503		729
	Income before provision for income taxes and partner’s interest		26,641		26,030
	Partner’s share of consolidated loss		101		133
	Provision for income taxes		9,052		8,372
Net Income:	Net income	$	17,690	$	17,791
	Earnings per share: Basic	$	0.54	$	0.51
	Earnings per share: Diluted	$	0.51	$	0.49
	Shares outstanding: Basic		32,955		34,775
	Shares outstanding: Diluted		34,439		36,437

IDEXX Laboratories, Inc. and Subsidiaries
Key Operating Ratios (Unaudited)

		Three Months Ended
		March 31, 2005			March 31, 2004
Key Operating
Ratios (as a
percentage of
revenue):	Gross profit		49.9	%		50.3	%
	Sales, marketing, general and administrative expense		26.4	%		24.9	%
	Research and development expense		6.4	%		6.4	%
	Income from operations		17.1	%		19.0	%
International
Revenue:	International revenue		35.1	%		31.3	%

IDEXX Announces First Quarter Results
April 29, 2005
Page 5 of 7

IDEXX Laboratories, Inc. and Subsidiaries
Segment Information
Amounts in thousands (Unaudited)

		Three Months Ended
		March 31, 2005			March 31, 2004
Revenue:	Companion Animal Group	$	124,880		$	109,830
	Water		12,806			11,854
	Food Diagnostics Group		14,740			11,733
	Total	$	152,426		$	133,417
Gross Profit:	Companion Animal Group	$	59,263		$	52,076
	Water		8,477			7,993
	Food Diagnostics Group		8,340			6,977
	Total	$	76,080		$	67,046
Income from
Operations:	Companion Animal Group	$	18,888		$	18,248
	Water		5,504			5,055
	Food Diagnostics Group		2,578			2,923
	Other		(832	)		(925	)
	Total	$	26,138		$	25,301
Gross Profit
(as a
percentage of	Companion Animal Group		47.5	%		47.4	%
revenue):	Water		66.2	%		67.4	%
	Food Diagnostics Group		56.6	%		59.5	%
Operating
Profit (as a
percentage of
revenue):	Companion Animal Group		15.1	%		16.6	%
	Water		43.0	%		42.6	%
	Food Diagnostics Group		17.5	%		24.9	%

IDEXX Laboratories, Inc. and Subsidiaries
Revenues by Product and Service Categories
Amounts in thousands (Unaudited)

		Three Months Ended
		March 31, 2005		March 31, 2004
Net CAG Revenue:
	Instruments and consumables	$	52,873	$	48,811
	Rapid assay products		24,752		24,245
	Laboratory and consulting services		36,544		27,105
	Information products and services and digital radiography		7,461		7,328
	Pharmaceutical products		3,250		2,341
	Net CAG revenue		124,880		109,830
Net Water
Revenue:			12,806		11,854
Net FDG Revenue:
	Production animal products		10,862		7,898
	Dairy-testing products		3,878		3,835
	Net FDG revenue		14,740		11,733
Net Revenue:		$	152,426	$	133,417

IDEXX Announces First Quarter Results
April 29, 2005
Page 6 of 7

IDEXX Laboratories, Inc. and Subsidiaries
Consolidated Balance Sheet
Amounts in thousands (Unaudited)

			March 31, 2005			December 31, 2004
Assets:	Current Assets:
	Cash and cash equivalents	$	44,579		$	47,156
	Short-term investments		65,622			90,116
	Accounts receivable, net		75,617			65,639
	Inventories		78,481			76,424
	Other current assets		22,045			22,257
	Total current assets		286,344			301,592
	Long-term investments		12,037			19,687
	Property and equipment - cost		140,714			137,851
	Less - Accumulated depreciation		77,970			75,221
	Property and equipment, net		62,744			62,630
	Other long-term assets, net		126,793			130,328
	Total assets	$	487,918		$	514,237
Liabilities and Stockholders’ Equity:
	Current Liabilities:
	Accounts payable	$	12,957		$	14,723
	Accrued expenses		62,951			73,785
	Notes payable		526			1,291
	Deferred revenue		8,617			10,153
	Total current liabilities		85,051			99,952
	Total long-term liabilities		15,080			16,233
	Partner’s interest in subsidiary		342			392
	Stockholders’ Equity:
	Common stock		4,533			4,522
	Additional paid-in capital		414,397			410,817
	Deferred equity-based compensation		1,174			665
	Retained earnings		336,372			318,682
	Treasury stock, at cost		(377,867	)		(348,327	)
	Accumulated other comprehensive income		8,836			11,301
	Total stockholders’ equity		387,445			397,660
	Total liabilities and stockholders’ equity	$	487,918		$	514,237

IDEXX Laboratories, Inc. and Subsidiaries
Key Balance Sheet Statistics (Unaudited)

		March 31, 2005		December 31, 2004
Key
Balance Sheet
Statistics:	Days sales outstanding		42		39
	Inventory turns		1.8		1.9

IDEXX Announces First Quarter Results
April 29, 2005
Page 7 of 7

IDEXX Laboratories, Inc. and Subsidiaries
Consolidated Statement of Cash Flows
Amounts in thousands (Unaudited)

		Three Months Ended
			March 31, 2005			March 31, 2004
Operating:	Cash Flows from Operating Activities:
	Net income	$	17,690		$	17,791
	Non-cash charges		6,390			11,663
	Changes in current assets and liabilities, net of acquisitions and disposals		(23,798	)		(18,786	)
	Net cash provided by operating activities	$	282		$	10,668
Investing:	Cash Flows from Investing Activities:
	Decrease in investments, net		32,112			443
	Purchase of property and equipment		(4,536	)		(6,003	)
	Acquisition of businesses and intangible assets		(659	)		(5,342	)
	Acquisition of equipment leased to customers		(696	)		(466	)
	Net cash provided by (used by) investing activities	$	26,221		$	(11,368	)
Financing:	Cash Flows from Financing Activities:
	Repayments of notes payable		(1,271	)		(254	)
	Purchase of treasury stock		(29,540	)		(22,417	)
	Proceeds from the exercise of stock options		2,603			11,005
	Net cash used by financing activities	$	(28,208	)	$	(11,666	)
	Net effect of exchange rate changes		(872	)		184
	Net decrease in cash and cash equivalents		(2,577	)		(12,182	)
	Cash and cash equivalents, beginning of period		47,156			96,942
	Cash and cash equivalents, end of period	$	44,579		$	84,760

IDEXX Laboratories, Inc. and Subsidiaries
Free Cash Flow
Amounts in thousands (Unaudited)

		Three Months Ended
		March 31, 2005			March 31, 2004
Free Cash
Flow:	Net cash provided by operating activities	$	282		$	10,668
	Purchase of property and equipment		(4,536	)		(6,003	)
	Acquisition of equipment leased to customers		(696	)		(466	)
	Free cash flow	$	(4,950	)	$	4,199
	Free cash flow indicates the cash generated from operations reduced by investments in capital and other long-term assets.  Free cash flow excludes financing activities, investments in monetary securities, and business acquisitions and divestitures.  We feel free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in fixed assets that are required to operate the business.  We believe this is a common financial measure useful to further evaluate the results of operations.